Jonathan Schoenfeld, MD, MPH - Evolving the Treatment Landscape in Head and Neck Squamous Cell Carcinoma: Promoting Apoptosis With Emerging Antagonists of Inhibitors of Apoptosis Proteins

Please visit answersincme.com/EEF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck squamous cell carcinoma (HNSCC) discusses the clinical significance of emerging antagonists of inhibitors of apoptosis proteins (IAPs) for patients with HNSCC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for emerging antagonists of IAPs for patients with resectable and unresectable locally advanced (LA) HNSCC; Review the clinical significance of emerging antagonists of IAPs in the treatment of unresectable LA HNSCC, based on the latest efficacy and safety data; and Outline strategies for how antagonists of IAPs may fit into future treatment algorithms for patients with resectable and unresectable LA HNSCC, as they become available.

There are no comments yet.

Please log in to write the first comment.